Elicio Therapeutics Correlations
ELTX Stock | 5.12 0.11 2.20% |
The current 90-days correlation between Elicio Therapeutics and Kiora Pharmaceuticals is 0.07 (i.e., Significant diversification). The correlation of Elicio Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Elicio Therapeutics Correlation With Market
Good diversification
The correlation between Elicio Therapeutics and DJI is -0.08 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Elicio Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
Elicio |
Moving together with Elicio Stock
Moving against Elicio Stock
0.73 | VALN | Valneva SE ADR Downward Rally | PairCorr |
0.71 | DRRX | Durect | PairCorr |
0.68 | DTIL | Precision BioSciences | PairCorr |
0.65 | VRCA | Verrica Pharmaceuticals | PairCorr |
0.63 | VRAX | Virax Biolabs Group | PairCorr |
0.61 | VCNX | Vaccinex | PairCorr |
0.5 | VINC | Vincerx Pharma | PairCorr |
0.47 | VIRX | Viracta Therapeutics | PairCorr |
0.46 | DYAI | Dyadic International | PairCorr |
0.44 | EQ | Equillium | PairCorr |
0.4 | VIGL | Vigil Neuroscience | PairCorr |
0.39 | DNTH | Dianthus Therapeutics | PairCorr |
0.38 | VERV | Verve Therapeutics | PairCorr |
0.37 | DRMA | Dermata Therapeutics | PairCorr |
0.36 | ME | 23Andme Holding | PairCorr |
0.68 | VTGN | VistaGen Therapeutics | PairCorr |
0.68 | ENTA | Enanta Pharmaceuticals | PairCorr |
0.63 | VXRT | Vaxart Inc | PairCorr |
0.59 | ENVB | Enveric Biosciences | PairCorr |
0.5 | EDIT | Editas Medicine | PairCorr |
0.48 | EDSA | Edesa Biotech Fiscal Year End 20th of December 2024 | PairCorr |
0.46 | ELEV | Elevation Oncology | PairCorr |
0.44 | VRPX | Virpax Pharmaceuticals | PairCorr |
0.42 | EPIX | ESSA Pharma Fiscal Year End 10th of December 2024 | PairCorr |
0.35 | EOLS | Evolus Inc | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Elicio Stock performing well and Elicio Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Elicio Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
KPRX | 2.77 | (0.29) | 0.00 | (0.26) | 0.00 | 5.95 | 16.59 | |||
ZVSA | 4.67 | (0.99) | 0.00 | 0.60 | 0.00 | 9.17 | 78.93 | |||
SONN | 4.76 | (0.77) | 0.00 | 2.19 | 0.00 | 12.31 | 37.58 | |||
ZURA | 3.78 | (0.36) | 0.00 | (0.09) | 0.00 | 7.95 | 30.69 | |||
PHIO | 4.53 | (0.30) | 0.00 | (0.18) | 0.00 | 11.78 | 36.22 | |||
RNAZ | 7.63 | 1.05 | 0.10 | (0.44) | 6.52 | 22.00 | 68.80 | |||
QNRX | 6.21 | 0.47 | 0.07 | 0.37 | 6.73 | 17.65 | 74.46 |
Elicio Therapeutics Corporate Management
Joy Seymour | VP Affairs | Profile | |
Esther Welkowsky | Senior Development | Profile | |
Peter DeMuth | Chief Officer | Profile | |
Michael DiVecchia | Senior Resources | Profile | |
Megan Filoon | Secretary Counsel | Profile | |
Brian Piekos | Chief Officer | Profile |